Literature DB >> 19494187

Differential inhibition of various adenylyl cyclase isoforms and soluble guanylyl cyclase by 2',3'-O-(2,4,6-trinitrophenyl)-substituted nucleoside 5'-triphosphates.

Srividya Suryanarayana1, Martin Göttle, Melanie Hübner, Andreas Gille, Tung-Chung Mou, Stephen R Sprang, Mark Richter, Roland Seifert.   

Abstract

Adenylyl cyclases (ACs) catalyze the conversion of ATP into the second messenger cAMP and play a key role in signal transduction. In a recent study (Mol Pharmacol 70:878-886, 2006), we reported that 2',3'-O-(2,4,6-trinitrophenyl)-substituted nucleoside 5'-triphosphates (TNP-NTPs) are potent inhibitors (K(i) values in the 10 nM range) of the purified catalytic subunits VC1 and IIC2 of membranous AC (mAC). The crystal structure of VC1:IIC2 in complex with TNP-ATP revealed that the nucleotide binds to the catalytic site with the TNP-group projecting into a hydrophobic pocket. The aims of this study were to analyze the interaction of TNP-nucleotides with VC1:IIC2 by fluorescence spectroscopy and to analyze inhibition of mAC isoforms, soluble AC (sAC), soluble guanylyl cyclase (sGC), and G-proteins by TNP-nucleotides. Interaction of VC1:IIC2 with TNP-NDPs and TNP-NTPs resulted in large fluorescence increases that were differentially reduced by a water-soluble forskolin analog. TNP-ATP turned out to be the most potent inhibitor for ACV (K(i), 3.7 nM) and sGC (K(i), 7.3 nM). TNP-UTP was identified as the most potent inhibitor for ACI (K(i), 7.1 nM) and ACII (K(i), 24 nM). TNP-NTPs inhibited sAC and GTP hydrolysis by G(s)- and G(i)-proteins only with low potencies. Molecular modeling revealed that TNP-GTP and TNP-ATP interact very similarly, but not identically, with VC1:IIC2. Collectively, our data show that TNP-nucleotides are useful fluorescent probes to monitor conformational changes in VC1:IIC2 and that TNP-NTPs are a promising starting point to develop isoform-selective AC and sGC inhibitors. TNP-ATP is the most potent sGC inhibitor known so far.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19494187      PMCID: PMC2729792          DOI: 10.1124/jpet.109.155432

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  38 in total

Review 1.  Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase.

Authors:  N Defer; M Best-Belpomme; J Hanoune
Journal:  Am J Physiol Renal Physiol       Date:  2000-09

2.  Crystallization of complex between soluble domains of adenylyl cyclase and activated Gs alpha.

Authors:  John J G Tesmer; Roger K Sunahara; David A Fancy; Alfred G Gilman; Stephen R Sprang
Journal:  Methods Enzymol       Date:  2002       Impact factor: 1.600

3.  The olfactory G protein G(alphaolf) possesses a lower GDP-affinity and deactivates more rapidly than G(salphashort): consequences for receptor-coupling and adenylyl cyclase activation.

Authors:  H Y Liu; K Wenzel-Seifert; R Seifert
Journal:  J Neurochem       Date:  2001-07       Impact factor: 5.372

4.  Quantitative analysis of formyl peptide receptor coupling to g(i)alpha(1), g(i)alpha(2), and g(i)alpha(3).

Authors:  K Wenzel-Seifert; J M Arthur; H Y Liu; R Seifert
Journal:  J Biol Chem       Date:  1999-11-19       Impact factor: 5.157

5.  Soluble adenylyl cyclase as an evolutionarily conserved bicarbonate sensor.

Authors:  Y Chen; M J Cann; T N Litvin; V Iourgenko; M L Sinclair; L R Levin; J Buck
Journal:  Science       Date:  2000-07-28       Impact factor: 47.728

6.  Molecular basis for P-site inhibition of adenylyl cyclase.

Authors:  J J Tesmer; C W Dessauer; R K Sunahara; L D Murray; R A Johnson; A G Gilman; S R Sprang
Journal:  Biochemistry       Date:  2000-11-28       Impact factor: 3.162

7.  Differential interactions of the catalytic subunits of adenylyl cyclase with forskolin analogs.

Authors:  Cibele Pinto; Melanie Hübner; Andreas Gille; Mark Richter; Tung-Chung Mou; Stephen R Sprang; Roland Seifert
Journal:  Biochem Pharmacol       Date:  2009-04-02       Impact factor: 5.858

8.  Distinct interactions of GTP, UTP, and CTP with G(s) proteins.

Authors:  Andreas Gille; Hui-Yu Liu; Stephen R Sprang; Roland Seifert
Journal:  J Biol Chem       Date:  2002-06-21       Impact factor: 5.157

9.  2'(3')-O-(N-methylanthraniloyl)-substituted GTP analogs: a novel class of potent competitive adenylyl cyclase inhibitors.

Authors:  Andreas Gille; Roland Seifert
Journal:  J Biol Chem       Date:  2003-02-03       Impact factor: 5.157

10.  Characterization of mouse heart adenylyl cyclase.

Authors:  Martin Göttle; Jens Geduhn; Burkhard König; Andreas Gille; Klaus Höcherl; Roland Seifert
Journal:  J Pharmacol Exp Ther       Date:  2009-03-23       Impact factor: 4.030

View more
  9 in total

1.  Cytidylyl and uridylyl cyclase activity of bacillus anthracis edema factor and Bordetella pertussis CyaA.

Authors:  Martin Göttle; Stefan Dove; Frieder Kees; Jens Schlossmann; Jens Geduhn; Burkhard König; Yuequan Shen; Wei-Jen Tang; Volkhard Kaever; Roland Seifert
Journal:  Biochemistry       Date:  2010-07-06       Impact factor: 3.162

2.  Structural basis for the high-affinity inhibition of mammalian membranous adenylyl cyclase by 2',3'-o-(N-methylanthraniloyl)-inosine 5'-triphosphate.

Authors:  Melanie Hübner; Anshuman Dixit; Tung-Chung Mou; Gerald H Lushington; Cibele Pinto; Andreas Gille; Jens Geduhn; Burkhard König; Stephen R Sprang; Roland Seifert
Journal:  Mol Pharmacol       Date:  2011-04-15       Impact factor: 4.436

3.  Structure-activity relationships for the interactions of 2'- and 3'-(O)-(N-methyl)anthraniloyl-substituted purine and pyrimidine nucleotides with mammalian adenylyl cyclases.

Authors:  Cibele Pinto; Gerald H Lushington; Mark Richter; Andreas Gille; Jens Geduhn; Burkhard König; Tung-Chung Mou; Stephen R Sprang; Roland Seifert
Journal:  Biochem Pharmacol       Date:  2011-05-18       Impact factor: 5.858

Review 4.  Inhibitors of membranous adenylyl cyclases.

Authors:  Roland Seifert; Gerald H Lushington; Tung-Chung Mou; Andreas Gille; Stephen R Sprang
Journal:  Trends Pharmacol Sci       Date:  2011-11-17       Impact factor: 14.819

Review 5.  International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases.

Authors:  Carmen W Dessauer; Val J Watts; Rennolds S Ostrom; Marco Conti; Stefan Dove; Roland Seifert
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

6.  Crystal structure and regulation mechanisms of the CyaB adenylyl cyclase from the human pathogen Pseudomonas aeruginosa.

Authors:  Hüsnü Topal; Nanette B Fulcher; Jacob Bitterman; Eric Salazar; Jochen Buck; Lonny R Levin; Martin J Cann; Matthew C Wolfgang; Clemens Steegborn
Journal:  J Mol Biol       Date:  2011-12-28       Impact factor: 5.469

Review 7.  Physiological roles of mammalian transmembrane adenylyl cyclase isoforms.

Authors:  Katrina F Ostrom; Justin E LaVigne; Tarsis F Brust; Roland Seifert; Carmen W Dessauer; Val J Watts; Rennolds S Ostrom
Journal:  Physiol Rev       Date:  2021-10-26       Impact factor: 37.312

8.  Identification of a haem domain in human soluble adenylate cyclase.

Authors:  Sabine Middelhaufe; Martina Leipelt; Lonny R Levin; Jochen Buck; Clemens Steegborn
Journal:  Biosci Rep       Date:  2012-10       Impact factor: 3.840

Review 9.  Structure/function of the soluble guanylyl cyclase catalytic domain.

Authors:  Kenneth C Childers; Elsa D Garcin
Journal:  Nitric Oxide       Date:  2018-04-25       Impact factor: 4.427

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.